Close Menu

NewGene

NEW YORK (GenomeWeb News) – Sequenom today said that it has launched a certified service program for its MassArray System and has named the first laboratory participants.

NewGene has launched a sequencing-based test on Roche's 454 GS FLX for Noonan syndrome and other related disorders.

NewGene's hereditary breast cancer test

NewGene is initially targeting the UK market and patients with an increased hereditary risk for breast cancer for its pyrosequencing-based assay.

The UK firm will provide services for NimbleGen Sequence Capture Arrays with sequencing on Roche 454's Genome Sequencer FLX System.

The company expects to use Roche's 454 technology to offer full-gene sequencing tests at a lower cost and faster turnaround time than existing providers using Sanger sequencing.

Paired Ends: Aug 4, 2009

Premium

David Huntley, Ann Curtis, Jonathan Robinson, Jonathan Coxhead, David Allison, John Burn, Michael Wright, Kary Mullis

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.